The Quantellect read.As of Nov 19, 2026, 5 active firms cover Karyopharm Therapeutics Inc: 4 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $3.00 to $28.00 (about 9.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $13.25 sits 76049% above the current $0.02. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.85 next quarter toward $-1.72 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy480%
Neutral120%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$13.25
+76049.4% upside
Average target across 4 active firms as of Nov 19, 2026 vs $0.02 current
Highest Target$28.00
Average Target$13.25
Lowest Target$3.00
Detailed analyst forecasts for KPTI
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 4 of 5 active firms rate KPTI a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
KPTI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.85
Range $-0.85 – $-0.85 · 1 analysts · -62% YoY
Next period, 1 analysts expect Karyopharm Therapeutics Inc to earn $-0.85 a share (range $-0.85 – $-0.85), versus $-2.23 a year earlier. Full-year consensus is $-4.10, growing to $-1.72 the year after.
REVENUE · NEXT QUARTER
$34.0M
Range $33.2M – $35.3M · 1 analysts · -0% YoY
Revenue is expected to reach $34.0M (range $33.2M – $35.3M), -0.3% year-over-year. Full-year consensus is $134.4M, rising to $159.9M next year.
Top analysts covering Karyopharm Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KPTI.
#1
Peter Lawson
Barclays · Rank #89
Buy
$10.00+57371.3% to target
Overall win rate
45%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Neutral
$3.00+17141.4% to target
Overall win rate
42%
+ Follow
#3
EW
Edward White
HC Wainwright & Co. · Rank #376
Buy
$56.00+321739.1% to target
Overall win rate
31%
+ Follow
#4
Edward Tenthoff
Piper Sandler · Rank #460
Buy
$7.00+40129.9% to target
Overall win rate
29%
+ Follow
#5
Brian Abrahams
RBC Capital · Rank #502
Buy
No targeton KPTI
Overall win rate
26%
+ Follow
KPTI stock forecast FAQ
What is KPTI's average 12-month price target?+
The 4 active firms with a live target average $13.25 for Karyopharm Therapeutics Inc over the next 12 months, ranging from a $28.00 high to a $3.00 low, as of Nov 19, 2026.
Is KPTI stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for KPTI?+
The Street-high target is $28.00 (Rodman & Renshaw), and the Street-low is $3.00 (HC Wainwright & Co.). The average of all 4 active-firm targets is $13.25.
How many active Wall Street firms cover KPTI?+
5 active firms have a recognized rating on Karyopharm Therapeutics Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering KPTI?+
Among analysts who currently cover KPTI, Peter Lawson of Barclays has the strongest overall Quantellect track record (Rank #89). Their current call is Buy with a $10.00 target.
What is Karyopharm Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.85 per share (range $-0.85 – $-0.85) across 1 analysts. Full-year EPS is projected at $-4.10, rising to $-1.72 the following year.
How much revenue is Karyopharm Therapeutics Inc expected to report next quarter?+
Consensus revenue is $34.0M (range $33.2M – $35.3M). Full-year revenue is projected at $134.4M, growing to $159.9M next year.
Have analysts been upgrading or downgrading KPTI lately?+
As of Nov 19, 2026, 4 of 5 active firms rate KPTI a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KPTI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.